sfondo pallini

Thomas Sabia
Chief Commercial Officer

close button

Tom Sabia joined as Chief Commercial Officer in February 2022.  He brings more than 20 years of drug commercialization and development experience across large, midsize, and small biotech organizations. Before joining EryDel, he was the Commercial Lead for Spark Therapeutics’ (a Roche Company) Liver Directed Gene Therapy Portfolio where he led commercialization of assets from pre-clinical through launch.  Prior to Spark, he spent three years at Sobi as Vice President of Marketing, Sales and Operations for Europe, Middle East, and North Africa leading the successful commercialization an organizational buildout of two innovative rare disease products. He has also held marketing, sales and operations leadership positions at CSL Behring and Sanofi Pharmaceuticals where during his tenure commercialized seven specialty and rare disease products.  Tom received an MBA and BA from Salisbury University’s Perdue School of Business.